Related Experiment Video

Updated: Jul 6, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Management of atrial fibrillation in patients with heart failure

Hans-Ruprecht Neuberger1, Christian Mewis, Dirk J van Veldhuisen

  • 1Klinik für Innere Medizin III, Kardiologie, Angiologie, und Internistische Intensivmedizin;, Universitätsklinikum des Saarlandes, D-66421 Homburg/Saar, Germany. h.neuberger@tiscali.de

European Heart Journal
|September 15, 2007
PubMed

Insights

Atrial fibrillation (AF) increases mortality in chronic heart failure (CHF) patients, though causality is unclear. New AF prevention strategies may improve survival and quality of life for those with heart failure.

Area of Science:

  • Cardiology
  • Internal Medicine
  • Clinical Research

Background:

  • Atrial fibrillation (AF) and chronic heart failure (CHF) are prevalent cardiovascular diseases that frequently occur together.
  • Limited data exist to guide the management of AF in patients diagnosed with CHF.

Purpose of the Study:

  • To review the prognostic significance of AF in CHF patients.
  • To examine rhythm and rate control strategies for AF in the context of CHF.
  • To explore preventive options for AF in individuals with ventricular dysfunction.

Main Methods:

  • Literature review of current research on AF and CHF.
  • Analysis of prognostic relevance, treatment strategies, and prevention options.
  • Synthesis of findings to guide clinical practice.

Main Results:

  • AF is linked to higher mortality rates in patients with CHF.
  • The causal relationship between AF and mortality in CHF remains uncertain.
  • Preventive strategies for AF show promise for improving outcomes.

Conclusions:

  • AF is associated with increased mortality in CHF patients, but a causal link requires further investigation.
  • Effective management strategies for AF in CHF patients are still evolving.
  • Emerging AF prevention methods offer potential benefits for quality of life and survival in CHF.

More Related Videos

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

Estimating Bilateral Atrial Function by Cardiovascular Magnetic Resonance Feature Tracking in Patients with Paroxysmal Atrial Fibrillation08:10

Estimating Bilateral Atrial Function by Cardiovascular Magnetic Resonance Feature Tracking in Patients with Paroxysmal Atrial Fibrillation

Published on: July 20, 2022

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.